Cipla to Distribute Sanofi’s CNS Products in India

Cipla to distribute Sanofi India’s central nervous system product range in India

Overview

Sanofi India Limited (SIL) and Sanofi Healthcare India Private Limited and Cipla Limited (Cipla) announced an exclusive partnership for distribution and promotion of Sanofi India’s central nervous system (CNS) product range in India.

Responsibilities Post Partnership

• As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category.
• While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.

Words from Sanofi India

Mr. Rodolfo Hrosz, managing director, Sanofi India Limited, said: “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”

Words from CEO: Cipla Limited

Achin Gupta, chief executive officer – One India Business, Cipla Limited, said: “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central nervous system is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”

Sanofi’s Innovative Pipeline

Sanofi India continues to focus on accelerating its strong innovation pipeline into India, across multiple therapeutic areas including diabetes, transplants, rare diseases, consumer healthcare and vaccines.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!